CN104840420B - It is a kind of to be used for Lactation of Dairy Cow phase metritic Cefquinome sulfate uterus injectant and preparation method thereof - Google Patents
It is a kind of to be used for Lactation of Dairy Cow phase metritic Cefquinome sulfate uterus injectant and preparation method thereof Download PDFInfo
- Publication number
- CN104840420B CN104840420B CN201510316219.7A CN201510316219A CN104840420B CN 104840420 B CN104840420 B CN 104840420B CN 201510316219 A CN201510316219 A CN 201510316219A CN 104840420 B CN104840420 B CN 104840420B
- Authority
- CN
- China
- Prior art keywords
- cefquinome sulfate
- cefquinome
- uterus
- vegetable oil
- uterus injectant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Cefquinome sulfate uterus injectant and preparation method thereof.The Cefquinome sulfate uterus injectant is made up of following supplementary materials：0.5 2.5g of Cefquinome sulfate (in terms of cefquinome), 0.125 1.25g of glyceryl monostearate, 0.125 1.25g of suspending agent, vegetable oil add to 25ml.Preparation technology is as follows：Take appropriate pretreated vegetable oil, add glyceryl monostearate heating fusing, be subsequently adding suspending agent, Cefquinome sulfate, then plus vegetable oil to full dose, grinding is uniform, obtains final product.The uterus injectant has the advantage that：Drug release is slow, and bioavailability is high, little to local tissue stimulation；It is administered by uterus local, is taken effect quick, it is to avoid the animal stress reaction that drug administration by injection causes；Medicine eliminates rapid, and it is short to abandon the milk phase, effectively prevent economic loss, with very high clinical generalization value.
Description
Technical field
The present invention relates to a kind of Cefquinome sulfate uterus injectant and preparation method thereof.
Background technology
Cow uteri (inner membrance) inflammation is common frequently-occurring disease in milk cow production, is focused mostly within 2 weeks puerperal, general to fall ill
Rate is 20%～35%, typically the mucus or purulent inflammation of uterine mucosa.As the noxious substance produced by inflammation can be caused
Necrospermia and embryo and become one of infertile common cause of milch cow, China's cow uteri (inner membrance) inflammation type infertility accounts for the mother that grows up
More than the 17% of cattle infertility.Uterus (inner membrance) inflammation can not only affect the heat of milch cow and gestation, reduce milk production of cow, lure
Send out the disease such as mastitiss, when serious, can also cause the forfeiture of cow reproduction ability, the acute infected cattle having can also cause septicemia and
Cause death.Therefore, harm of the disease to dairy is quite serious, can cause larger economic loss.
Cefquinome (Cefquinome), is also called HOE 111. or Cefquinome, is the forth generation cephalo of animal specific
Bacteriums antibiotic.Cefquinome reaches bactericidal effect by suppressing the synthesis of cell wall, and its has a broad antifungal spectrum, antibacterial activity are strong,
Good antibacterial activity is shown to most of G+ bacterium and G- bacterium, especially to staphylococcus aureuses, streptococcus, bacillus pyocyaneus
There is relatively low Mlc with the member of Colibacter, also have work to penicillin-fast staphylococcuses and enterococcus in addition
Property.Cefquinome is highly stable to beta-lactamase.Cefquinome is registered in China, is mainly used in treatment killing property Pasteur's bar more
The porcine respiratory disease that bacterium or Actinobacillus pleuropneumoniae cause.
Existing Cefquinome sulfate injection, injectable powder mainly by administered intramuscular, are extremely difficult to inside uterus,
Not as uterus local application effect it is good.Therefore, exploitation is a kind of has suitable for the cefquinome uterus injection preparation that milch cow uses
Important realistic meaning.
The content of the invention
It is an object of the invention to provide a kind of Cefquinome sulfate uterus injectant and preparation method thereof.
Cefquinome sulfate uterus injectant provided by the present invention, is made up of following supplementary materials：Cefquinome sulfate is (former
Material medicine) 0.5-2.5g (in terms of cefquinome), glyceryl monostearate 0.125-1.25g, suspending agent 0.125-1.25g, plant
Oil adds to 25ml.
The Cefquinome sulfate uterus injectant further can be made up of following supplementary materials：Cefquinome sulfate (raw material
Medicine) 0.9-2.5g (in terms of cefquinome), glyceryl monostearate 0.125-1.25g, suspending agent 0.125-1.25g, vegetable oil
Add to 25ml.
Wherein, the vegetable oil specifically may be selected from following at least one：Soybean oil, Oleum Camelliae, Semen Maydis oil, Oleum Arachidis hypogaeae semen and Semen Gossypii
Oil.The vegetable oil can be further soybean oil.
The suspending agent specifically may be selected from following at least one：Tween 80, sorbester p17 and soybean phospholipid.The suspending agent enters
One step can be sorbester p17.
The particle diameter of the cefquinome sulfate raw material medicine can be 5-10 μm.
The character of Cefquinome sulfate uterus injectant of the present invention is off-white color to faint yellow oleagenous suspension.
The preparation method of above-mentioned Cefquinome sulfate uterus injectant, by vegetable oil, glyceryl monostearate and suspending agent
Macromolecular compound dicyandiamide solution is made, then the aseptic micropowder of Cefquinome sulfate is added, continued agitation grinding and make sulphuric acid
Cefquinome uterus injectant.
Concrete preparation method comprises the steps：
1) by after appropriate vegetable oil and glyceryl monostearate mixing, heating fusing obtains mixed system；
2) suspending agent, Cefquinome sulfate are added in the mixed system, then plus vegetable oil to full dose, grinding is uniform,
Obtain final product the Cefquinome sulfate uterus injectant.
Wherein, step 1) described in the condition that heats be：60～80 DEG C heat 15～30 minutes.Step 1 under normal circumstances)
Used in vegetable oil consumption for vegetable oil total amount 40%-60%.
Step 2) described in grind and can carry out in colloid mill.
The vegetable oil is using the front pretreatment also needed through filtration and heat sterilization.The condition of the heat sterilization
For：150-160 DEG C of sterilizing 2-3 hour.
Cefquinome sulfate uterus injectant provided by the present invention has significant curative effect to Lactation of Dairy Cow phase metritiss.Sulfur
Sour cefquinome uterus injectant (lactation period) is clinically used for treating the scorching consumption of cow uteri：1 (25ml:0.9g)/time,
Interval is administered twice for 72 hours.
Compared with prior art, the present invention has the advantages that：
(1) convenient drug administration is quick, reduces substantial amounts of manpower and materials；
(2) animal stress reaction is little, reduces the damage of animal body；
(3) simple production process, the preparation for obtaining is uniform, dispersibility, good stability, it is easy to extension production；
(4), for injection, drug release is slow for this preparation, and bioavailability is high, to tissue irritation
Low, clinical efficacy is notable, with high promotional value.
Specific embodiment
With reference to specific embodiment, the present invention is further illustrated, but the invention is not limited in this.
Experimental technique described in following embodiments, if no special instructions, is conventional method；The reagent and material, such as
Without specified otherwise, can be obtained by commercial sources.
The Cefquinome sulfate uterus injectant that the present invention is provided is a kind of preparation being evenly distributed, concrete preparation method bag
Include following steps：
A. vegetable oil (such as neutral soybean oil) Jing is filtered and is let cool after heat sterilization；
B. appropriate pretreated vegetable oil is taken, the glyceryl monostearate of 0.125-1.25g is added；
C.60～80 DEG C heat 15～30 minutes, treat tristerin melt, after stirring, be cooled to 40 DEG C it is left
The right side, adds suspending agent (such as sorbester p17), the Cefquinome sulfate (grain of 0.5-2.5g (in terms of cefquinome) of 0.125-1.25g
5-10 μm of footpath), then add vegetable oil to total amount be 25ml；
D. grind uniform, Cefquinome sulfate uterus injectant is obtained；
F. medicine is loaded and is injected in pipe, sealed, sterilizing, lamp inspection, packaging.
Detection method in following embodiments to the sedimentation granularity of uterus injectant：Apparatus plug graduated cylinder takes test sample 50ml,
Close plug, firmly shakes 1 minute, writes down the beginning height H0 of suspension, stands 3 hours, writes down the final height H of suspended matter, press
Following formula is calculated, as a result as follows：Sedimentation specific volume F=H/H0, is not less than 0.90 i.e. qualified.
The method of steriling test：
This product 11 is taken, is added in 400ml buffering sterile solution of the peptones containing 6% tween 80 (0.1%), fully
Mix, add penicillinase (being no less than 66,000,000 units), mix homogeneously to put 37 DEG C and be incubated 4 hours；Need testing solution is taken, according to
Method checks (annex page 137, direct inoculation), should meet regulation.
The prescription screening of embodiment 1, Cefquinome sulfate uterus injectant
1st, in prescription, the screening of glyceryl monostearate content (is noted：Glyceryl monostearate abbreviation glyceride in table)
Table 1
Preparation method is as follows：
1) Cefquinome sulfate aseptic powder Jing micronizing is obtained into the aseptic micropowder of Cefquinome sulfate (5-10 μm of particle diameter)；
2) soybean oil is put into standby at room temperature Jing filtering with after heat sterilization (150 DEG C sterilize 3 hours)；
3) appropriate pretreated soybean oil is taken, tristerin and suspending agent sorbester p17 is added；Heat and stir
(80 DEG C heat 15 minutes), after treating that tristerin melts, adds Cefquinome sulfate；
5) grind uniform in aseptic colloid mill, Cefquinome sulfate uterus injectant is obtained.
As seen from the results in Table 1, when the content of glyceryl monostearate is 0.3% (w/v), the sedimentation index of product is not up to
To the requirement of quality standard；When the content of glyceryl monostearate is 0.5～5.0% (w/v), the indices of product have reached
Meet full the requirement of quality standard, it is thus determined that the content of glyceryl monostearate is 0.5～5.0% (w/v) in prescription.
2nd, in prescription Arlacel-80 content screening
Table 2
Preparation method is ibid.
As seen from the results in Table 2, when the content of Arlacel-80 is 0.3% (w/v), the sedimentation index of product does not reach quality
The requirement of standard；When the mass content of Arlacel-80 is 0.5～5.0% (w/v), the indices of product reach and comply fully with matter
The requirement of amount standard, it is thus determined that Arlacel-80 content is 0.5～5.0% (w/v) in prescription.
Embodiment 2, prepare Cefquinome sulfate uterus injectant
Preparation method is as follows：
1) Cefquinome sulfate aseptic powder Jing micronizing is obtained into the aseptic micropowder of 5-10 μm of Cefquinome sulfate of particle diameter；
2) soybean oil is put into standby at room temperature Jing filtering with after heat sterilization (150 DEG C sterilize 3 hours)；
3) appropriate pretreated soybean oil (for the 40%-60% of the total consumption of soybean oil) is taken, glycerol monostearate is added
Ester；(80 DEG C heat 15 minutes) is heated and stirred, is treated that glyceryl monostearate melts, after stirring, is cooled to 40 DEG C, add
Sorbester p17, Cefquinome sulfate, then Oleum Glycines are increased to full dose；
4) grind uniform in aseptic colloid mill, Cefquinome sulfate uterus injectant is obtained.
The character of gained Cefquinome sulfate uterus injectant is off-white color to faint yellow oleagenous suspension.
The said goods are carried out settling granularity and Sterility testing, which meets the quality standard of uterus injectant.
Embodiment 3, prepare Cefquinome sulfate uterus injectant
Preparation method is as follows：
1) Cefquinome sulfate aseptic powder Jing micronizing is obtained into the aseptic micropowder of 5-10 μm of Cefquinome sulfate of particle diameter；
2) soybean oil is put into standby at room temperature Jing filtering with after heat sterilization (150 DEG C sterilize 3 hours)；
3) appropriate pretreated soybean oil (for the 40%-60% of the total consumption of soybean oil) is taken, glycerol monostearate is added
Ester；(80 DEG C heat 15 minutes) is heated and stirred, is treated that glyceryl monostearate melts, after stirring, is cooled to 40 DEG C, add
Sorbester p17, Cefquinome sulfate, then Oleum Glycines are increased to full dose；
4) grind uniform in aseptic colloid mill, Cefquinome sulfate uterus injectant is obtained.
The character of gained Cefquinome sulfate uterus injectant is off-white color to faint yellow oleagenous suspension.
The said goods are carried out settling granularity and Sterility testing, which meets the quality standard of uterus injectant.
Embodiment 4, prepare Cefquinome sulfate uterus injectant
Preparation method is as follows：
1) Cefquinome sulfate aseptic powder Jing micronizing is obtained into the aseptic micropowder of 5-10 μm of Cefquinome sulfate of particle diameter；
2) Oleum Camelliae is put into standby at room temperature Jing filtering with after heat sterilization (160 DEG C sterilize 2 hours)；
3) appropriate pretreated Oleum Camelliae (for the 40%-60% of the total consumption of Oleum Camelliae) is taken, glyceryl monostearate is added；Plus
Heat is simultaneously stirred (60 DEG C heat 30 minutes), is treated that glyceryl monostearate melts, after stirring, is cooled to 40 DEG C, adds span
80th, Cefquinome sulfate, then Oleum Glycines are increased to full dose；
4) grind uniform in aseptic colloid mill, Cefquinome sulfate uterus injectant is obtained.
The character of gained Cefquinome sulfate uterus injectant is off-white color to faint yellow oleagenous suspension.
The said goods are carried out settling granularity and Sterility testing, which meets the quality standard of uterus injectant.
Embodiment 5, prepare Cefquinome sulfate uterus injectant
Preparation method is as follows：
1) Cefquinome sulfate aseptic powder Jing micronizing is obtained into the aseptic micropowder of 5-10 μm of Cefquinome sulfate of particle diameter；
2) Semen Maydis oil is put into standby at room temperature Jing filtering with after heat sterilization (150 DEG C sterilize 2 hours)；
3) appropriate pretreated Semen Maydis oil (for the 40%-60% of the total consumption of Semen Maydis oil) is taken, glycerol monostearate is added
Ester；(80 DEG C heat 30 minutes) is heated and stirred, is treated that glyceryl monostearate melts, after stirring, is cooled to 40 DEG C, add
Tween 80, Cefquinome sulfate, then Oleum Glycines are increased to full dose；
4) grind uniform in aseptic colloid mill, Cefquinome sulfate uterus injectant is obtained.
The character of gained Cefquinome sulfate uterus injectant is off-white color to faint yellow oleagenous suspension.
The said goods are carried out settling granularity and Sterility testing, which meets the quality standard of uterus injectant.
Embodiment 6, prepare Cefquinome sulfate uterus injectant
Preparation method is as follows：
1) Cefquinome sulfate aseptic powder Jing micronizing is obtained into the aseptic micropowder of 5-10 μm of Cefquinome sulfate of particle diameter；
2) Oleum Gossypii semen is put into standby at room temperature Jing filtering with after heat sterilization (150 DEG C sterilize 2 hours)；
3) appropriate pretreated Oleum Gossypii semen (for the 40%-60% of the total consumption of Oleum Gossypii semen) is taken, glycerol monostearate is added
Ester；(80 DEG C heat 15 minutes) is heated and stirred, is treated that glyceryl monostearate melts, after stirring, is cooled to 40 DEG C, add
Soybean phospholipid, Cefquinome sulfate, then Oleum Glycines are increased to full dose；
5) grind uniform in aseptic colloid mill, Cefquinome sulfate uterus injectant is obtained.
The character of gained Cefquinome sulfate uterus injectant is off-white color to faint yellow oleagenous suspension.
The said goods are carried out settling granularity and Sterility testing, which meets the quality standard of uterus injectant.
The vivo efficacy test of embodiment 7, Cefquinome sulfate uterus injectant
1) safety testing of the Cefquinome sulfate uterus injectant to milch cow
The scorching healthy cow of 10 ametria in puerperal (inner membrance) is randomly choosed in large-scale milch cow farms, be prepared by embodiment 3
One (25ml of Cefquinome sulfate uterus injectant:Intrauterine is slowly injected by inseminating tube 0.9g).Every 72 hours
Medication 1 time, continuous use 2 times.It is before record milch cow mark, observing time, date of test and time, every cow head administration and last
The parameter such as the milk yield of 1,3,5,7,10 days and body temperature after single administration.Cow uteri and vaginal secretion principle are observed by palpation
The clinical symptoms such as condition.0 day before administration, the 10th day after last time administration, gather intrauterine contents row bacteriology checking.Mainly
Separating Escherichia coli, staphylococcuses, streptococcus, corynebacterium pyogeneses.It is true according to the above-mentioned data and result of clinical detection collected
Surely prevent and treat cow uteri (inner membrance) inflammation safety of the product to target animals.
As a result show, significant change, milk are had no before the parameters such as the milk yield and body temperature after the administration of each time point with administration
The clinical symptoms such as cattle uterus and vaginal secretionies situation.Before administration 0 day and administration after the 10th day respectively gather uterine secretion thing
And separation of bacterial, after showing administration, Detection of pathogenic bacteria number is reduced compared with before administration.Show based on the above results, milch cow is according to recommendation
After spacing of doses gives Cefquinome sulfate uterus injectant for 72 hours twice, milch cow is had no adverse reaction, said preparation with compared with
High safety.
2) residue test of the Cefquinome sulfate uterus injectant in Lac Bovis seu Bubali
Milch cow inclusion criteria is ametria (inner membrance) inflammation and the healthy cow of associated clinical symptoms, milch cow 30 days before the test
Inside non-general or intrauterine give antibiotic.The healthy milk of 12 ametrias (inner membrance) inflammation of experimental selection and associated clinical symptoms
Cattle, during test, milch cow is normally raised.Before administration, first uterus is cleaned with normal saline, rounded plastic pipe is inserted into intrauterine, will
One (25ml of Cefquinome sulfate uterus injectant prepared by embodiment 3:Intrauterine is injected by inseminating tube 0.9g), per head
Niu Yizhi, is used in conjunction twice, is spaced 72h.The blank milk sample of collection before administration, every cattle 12h, 18h, 24h after last time is administered,
36h, 42h, 48h, 60h, 66h, 72h, 84h, 90h, 96h gather composite sample 40ml, preserve to be measured under the conditions of being placed in -40 DEG C.
When noting milking, first three milk can not be given up.
Milk sample nitrogen Jing after acetonitrile extraction twice is dried up, and crosses the purification of HLB solid phase extraction columns, using UPLC-MS- after redissolution
The newborn drug concentration of MS methods detection.As a result after showing administration, in Lac Bovis seu Bubali, cefquinome eliminates rapid, 36 hours newborn Chinese medicine after administration
Thing concentration is calculated using off-drug period software for calculation WTM1.4 less than MRL (MRL) 20ug/kg in EMEA defineds breast
Afterwards, this preparation is 39.8 hours in the off-drug period of Lac Bovis seu Bubali, it is contemplated that clinical practice service condition, fixes tentatively Cefquinome sulfate uterus
After pressing recommended dose and recommending course for the treatment of administration, the milk phase of abandoning of milk is 48 hours to injectant.
3) Cefquinome sulfate uterus injectant is to the scorching pharmacodynamics test of cow uteri
Randomly choose in large-scale milch cow farms and suffer from the scorching milch cow development test in uterus (inner membrance) 40 puerperal, be randomly divided into 4
Group, 10 per group.Wherein 3 test medicine groups (I, II, III group), give high (2/time, interval administration two in 72 hours respectively
It is secondary), in (1/time, interval be administered twice within 72 hours), the sulphuric acid head of low (1/2/time, interval are administered twice for 72 hours) dosage
Spore quinoline oxime uterus injectant；1 drug control group (IV groups), gives florfenicol uterus injectant 1.Above-mentioned sulphuric acid cephalo quinoline
Oxime uterus injectant is sample prepared by embodiment 3, and specification is 25ml：0.9g
It is whole test during observed to milch cow is administered in detail, before being administered after record on-test, after administration and be discontinued
Afterwards the performance of each group milch cow clinical symptoms and the generation of symptom, develop, lapse to and Disappearance Scenarios, the body of recording medicine milch cow
The clinical symptoms such as temperature, milk yield and red, swollen, hot, pain, carry out rectal palpation to cow uteri, and observation whether there is the clinics such as swelling
Symptom.The 14th day after last time administration, the mucus sample of 1 every Fructus Arctii cervix uteri and vagina is gathered, bacteria distribution training is carried out
Support (escherichia coli, staphylococcuses, streptococcus, corynebacterium pyogeneses).It is true according to the above-mentioned data and result of clinical detection collected
The effectiveness of fixed output quota product.
According to result of the test, can be drawn a conclusion：
(1) after test medicine and control drug administration, each experimental group milch cow is administered uterine secretion thing after front and administration
Middle Main Pathogenic Bacteria quantity changes.Cefquinome sulfate uterus injectant high dose group is reduced to administration by 13 plants of bacterium before being administered
2 plants of bacterium afterwards；Cefquinome sulfate uterus injectant middle dose group is reduced to 3 plants of bacterium after administration by 17 plants of bacterium before being administered；
Cefquinome sulfate uterus injectant low dose group is reduced to 5 plants of bacterium after administration by 14 plants of bacterium before being administered；Control drug group
7 plants of bacterium after administration are reduced to by 15 plants of bacterium before being administered.Wherein Cefquinome sulfate uterus injectant high dose group and middle dose
Amount group therapeutic effect substantially, has good scavenging action to cow uteri inflammation Main Pathogenic Bacteria.Cefquinome sulfate uterus is injected
Agent low dose group is halved due to dosage, unsatisfactory to the elimination effect of cow uteri inflammation Main Pathogenic Bacteria.Control drug
Scavenging action of the group to cow uteri inflammation Main Pathogenic Bacteria is also not up to promising result.Illustrate high, the sulphuric acid cephalo quinoline of middle dosage
Oxime uterus injectant is to cow uteri inflammation Main Pathogenic Bacteria escherichia coli, streptococcus, staphylococcus aureuses and suppurative bar-shaped
The scavenging action of bacillus is significantly better than that low dosage Cefquinome sulfate uterus injectant and florfenicol uterus injectant.
The isolation identification result statistics of the main pathogenic fungi before and after 3 each test group milch cow medication of table
(2) Cefquinome sulfate uterus injectant and florfenicol uterus injectant treatment cow uteri are scorching, before administration by
In there is inflammation, each experimental group milch cow body temperature is slightly raised, and after administration, each time point milch cow body temperature gradually recovers normal.Treatment
The various clinical symptoms such as the spiritual appetite state of milch cow, lacation, vaginal secretionies and uterine state are obtained for significantly afterwards
Improve (P ＜ 0.01), wherein the effect is significant of high, middle dosage Cefquinome sulfate uterus injectant is better than low dosage sulphuric acid cephalo
Quinoline oxime uterus injectant and florfenicol uterus injectant (P ＜ 0.01), and high, middle dose group therapeutic effect is without significant difference
(P ＞ 0.05).
(3) high (2 times of recommended doses), in (recommended dose), Cefquinome sulfate of low (1/2 times of recommended dose) dosage
Palace injectant is respectively 90%, 80% and 60% to the scorching effective percentage of cow uteri；Florfenicol uterus injectant (matched group)
It is 60% to the scorching effective percentage of cow uteri.In terms of cure rate, high (2 times of recommended doses), in (recommended dose), it is low that (1/2 times pushes away
Recommend dosage) the Cefquinome sulfate uterus injectant of dosage is respectively 80%, 70% and to the scorching cure rate of cow uteri
50%；Florfenicol uterus injectant (matched group) is 50% to the scorching cure rate of cow uteri.
4 test medicine of table and control drug are to the scorching cure rate of cow uteri and effective percentage
(4) in view of high (2 times of recommended doses), in (recommended dose) dosage Cefquinome sulfate uterus injectant to milch cow
Metritic curative effect (pathogen elimination effect, clinical symptoms recovery situation) difference is not notable, and (1/2 times pushes away to be superior to low dosage
Recommend dosage), therefore recommend Cefquinome sulfate uterus injectant to be clinically used for preventing and treating the scorching therapeutic regimen of cow uteri and be：1/
Secondary, interval is administered twice for 72 hours.
The method that vivo efficacy according to embodiment 7 is tested carries out identical test to the product of embodiment 2,4,5,6, its
As a result it is suitable with the effect of embodiment 3.Show that the Cefquinome sulfate uterus injectant of present invention offer is safe and effective, biological sharp
Expenditure is high, little to local tissue stimulation, evident in efficacy, with high promotional value.
Claims (2)
1. a kind of Cefquinome sulfate uterus injectant, is made up of following supplementary materials：Cefquinome sulfate 0.90-1.25g, list are hard
Glycerol 0.125-1.25g, suspending agent 0.125-1.25g, vegetable oil add to 25ml；The quality of the Cefquinome sulfate
In terms of cefquinome；
The vegetable oil is soybean oil；
The suspending agent is sorbester p17；
The particle diameter of the Cefquinome sulfate is 5-10 μm；
The Cefquinome sulfate uterus injectant is used for the prevention and/or treatment of cow endometritis；
The Cefquinome sulfate uterus injectant is prepared according to the method for comprising the steps：
1) by after the appropriate vegetable oil and glyceryl monostearate mixing, heating fusing obtains mixed system；
The consumption of the vegetable oil for vegetable oil total amount 40%～60%；
The condition of the heating is：60～80 DEG C heat 15～30 minutes；
2) suspending agent, the Cefquinome sulfate are added in the mixed system, then plus vegetable oil to full dose, grinding is equal
It is even, obtain final product the Cefquinome sulfate uterus injectant；
The grinding is carried out in colloid mill；
The vegetable oil is using the front pretreatment also needed through filtration and heat sterilization；The condition of the heat sterilization is：
150-160 DEG C of sterilizing 2-3 hour.
2. the Cefquinome sulfate uterus injectant described in claim 1 is preparing prevention and/or is treating cow endometritis
Application in medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510316219.7A CN104840420B (en) | 2014-11-18 | 2015-06-10 | It is a kind of to be used for Lactation of Dairy Cow phase metritic Cefquinome sulfate uterus injectant and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014106544413 | 2014-11-18 | ||
| CN201410654441 | 2014-11-18 | ||
| CN201510316219.7A CN104840420B (en) | 2014-11-18 | 2015-06-10 | It is a kind of to be used for Lactation of Dairy Cow phase metritic Cefquinome sulfate uterus injectant and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104840420A CN104840420A (en) | 2015-08-19 |
| CN104840420B true CN104840420B (en) | 2017-04-05 |
Family
ID=53840671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510316219.7A Active CN104840420B (en) | 2014-11-18 | 2015-06-10 | It is a kind of to be used for Lactation of Dairy Cow phase metritic Cefquinome sulfate uterus injectant and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104840420B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334732A (en) * | 2017-07-07 | 2017-11-10 | 中国农业科学院饲料研究所 | A kind of rifaximin uterus injectant and preparation method and application |
| CN111714501A (en) * | 2020-07-03 | 2020-09-29 | 杭州爱力迈动物药业有限公司 | Method for improving dissolution rate of cefquinome sulfate and dissolution rate detection method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003063877A1 (en) * | 2002-02-01 | 2003-08-07 | Akzo Nobel N.V. | Cefquinome composition for intra-mammary administration in cattle |
| CN101214222A (en) * | 2007-12-27 | 2008-07-09 | 陆广富 | Injection for treating cow escherichia coli mastitis and pig bacterial respiratory tract infection and preparation thereof |
| CN102488694B (en) * | 2011-12-21 | 2012-12-19 | 齐鲁动物保健品有限公司 | Perfusion medicament for treating milk cow mastitis and preparation method thereof |
| CN103893108A (en) * | 2012-12-28 | 2014-07-02 | 瑞普（天津）生物药业有限公司 | Breast injectant prescription of cefquinome sulfate in dry milk period and preparation method thereof |
| CN104127419B (en) * | 2014-08-12 | 2016-09-28 | 中国药科大学 | A kind of stable Cefquinome sulfate oil suspension type injection |
-
2015
- 2015-06-10 CN CN201510316219.7A patent/CN104840420B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104840420A (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104873462B (en) | A kind of milch cow dry breast phase Cefquinome sulfate breast injection and preparation method thereof | |
| CN102247318B (en) | Oxytetracycline uterus injectant and preparation method thereof | |
| CN101953841B (en) | Swine eperythrozoonosis-resisting compound long-acting oxytetracycline injection and preparation method thereof | |
| CN104288356B (en) | Treat traditional Chinese medicine infusion solution of mastitis for milk cows and preparation method thereof | |
| CN104546703B (en) | A kind of Lactation of Dairy Cow phase is with Cefquinome sulfate breast injection and preparation method thereof | |
| CN104840420B (en) | It is a kind of to be used for Lactation of Dairy Cow phase metritic Cefquinome sulfate uterus injectant and preparation method thereof | |
| CN102488694B (en) | Perfusion medicament for treating milk cow mastitis and preparation method thereof | |
| CN102000145B (en) | Traditional Chinese medicine and western medicine compound infusion liquid for preventing and treating endometritis of dam and preparing method thereof | |
| CN104546704B (en) | A kind of milk cow dry breast phase Ceftiofur Hydrochloride breast injection and preparation method thereof | |
| CN103223021A (en) | Uterine infusion drug for preventing and treating endometritis of dairy cows and sows and preparation method of uterine infusion drug | |
| CN103142683B (en) | Be used for the treatment of Chinese medicinal perfusion liquid containing Herba Sophorae alopecuroidis total alkali of bovine mastitis and endometritis and preparation method thereof | |
| AU2011101378A4 (en) | Traditional Chinese medicine perfusate for the treatment of dairy cow mastitis and a preparation method thereof | |
| CN107334732A (en) | A kind of rifaximin uterus injectant and preparation method and application | |
| CN109432092A (en) | A kind of lactation period compounded antibiotic preparation and the preparation method and application thereof | |
| CN104586855A (en) | Compound rifaximin uterus injectant as well as preparation method and application thereof | |
| CN101953871B (en) | Antibacterial medicament for animals and preparation method and application thereof | |
| CN103721240A (en) | Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation | |
| CN103356690B (en) | Injection for treating sow endometritis and preparation method thereof | |
| CN105287374A (en) | Preparation method of cefquinome sulfate breast injectant and obtained preparation | |
| CN106138369A (en) | A kind of pharmaceutical composition preventing and treating animal endometritis and preparation method thereof | |
| CN108478524A (en) | Ketoprofen injection and its preparation method and application | |
| CN109045044A (en) | A kind of compound medicine and preparation method thereof, purposes | |
| CN115721677B (en) | Traditional Chinese medicine composition for preventing and treating calf bacterial diarrhea, and preparation method and application thereof | |
| CN103768104B (en) | A kind of treat medicine of animal endometritis and preparation method thereof | |
| CN107625810B (en) | Compound macleaya cordata composition preparation for treating animal diarrhea diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |